Education
About Us
Working with TipRanks
Follow Us
AxoGen (AXGN)
NASDAQ:AXGN
AXGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.90 - $21.00
Previous CloseN/A
Volume66.42K
Average Volume (3M)609.94K
Market Cap
$535.60M
Enterprise ValueN/A
Total Cash (Recent Filing)$33.48M
Total Debt (Recent Filing)$68.69M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 06, 2025EPS Estimate
0.06Last Dividend Ex-Date
Jan 27, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding45,544,044
10 Day Avg. Volume1,009,649
30 Day Avg. Volume609,936
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)7.93
Price to Sales (P/S)0.00
P/FCF Ratio630.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$24.50Price Target Upside108.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
AxoGen News
PremiumCompany Announcements
AxoGen’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Axogen Reports Strong Q1 2025 Revenue Growth---
Bulls Say, Bears Say
Bulls Say
Market PositionAXGN is expected to experience higher growth in the second half of the year, reflecting typical historical patterns.
Revenue GrowthManagement noted +17% y/y revenue growth was driven by enhanced sales productivity and commercial execution, which provides incremental confidence in the +15-20% LRP revenue CAGR.
Bears Say
Financial Performance1Q25 GM of 71.9% fell 260bps vs. consensus 74.5% and Adjusted EBITDA margin of 5.9% fell 306bp vs. cons. 9.0%.
Operational ChallengesThe 23% sell-off is attributed to disappointing gross margin, unexpected inventory write-offs, the departure of CFO Nir Naor, and slower-than-expected breast sales specialist hiring.
---
Ownership Overview
2.55% Insiders
17.53% Mutual Funds
37.64% Other Institutional Investors
28.36% Public Companies and Individual Investors
AXGN FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was $5.90 and its highest was $21.00 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $535.60M.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Aug 06, 2025 which is in 77 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on May 08, 2025. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of $0.015 by -$0.035.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $1 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.06.
How many shares outstanding does AxoGen have?
AxoGen has 45,544,044 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of -$0.02 in its last earnings report, missing expectations of $0.015. Following the earnings report the stock price went down -23.185%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in AXGN
---
AxoGen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (108.33% Upside)
$24.50 (108.33% Upside)
Blogger Sentiment
Bullish
AXGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 31.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.4%
Last 30 Days ▲ 17.2%
Last 30 Days ▲ 17.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
94.70%
12-Months-Change
Fundamentals
Return on Equity
-7.22%
Trailing 12-Months
Asset Growth
5.17%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc. (AXGN) is a leading medical technology company specializing in the development and commercialization of innovative surgical solutions for peripheral nerve injuries. The company's core products include nerve repair, nerve protection, and nerve grafting technologies, which are designed to support the body's own healing processes and improve the quality of life for patients with nerve damage. AxoGen operates primarily in the healthcare sector, focusing on providing surgeons with advanced tools and techniques to repair and reconstruct peripheral nerves.
---
AXGN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and strategic advancements, particularly in high-potential accounts and the BLA process for Avance Nerve Graft. However, challenges such as a decline in gross margin, delayed hiring for the breast segment, and the inability to implement process improvements until after BLA approval were noted. Overall, the positive aspects, including revenue growth and strategic execution, outweigh the challenges.Read More>---
AXGN Stock 12 Month Forecast
Average Price Target
$24.50
▲(108.33% Upside)
Technical Analysis
---